Trio of New Options Ideas

Fresh Options Trifecta

We’ve got a trio of new options ideas to present this morning. Facebook and Starbucks just reported earnings yesterday in the post-market, and we have significant Form-4 buys at a bottom on TNET.

We have formulated an options idea for all of those chains. Some quick-strike plays for our earnings reporters, and a longer-term look for the Form-4:

TriNet Group, Inc. TNET 12/20 $55 Calls
Facebook, Inc. FB Weekly $190-195 Calls
Starbucks Corp. SBUX Weekly $85.50-87 Calls 

Visium Technologies, Inc. VISM

Just a reminder for those of our readers who may not have caught yesterday’s report. We initiated three moths of coverage on VISM, and compiled an introductory report on the company in lieu of our regular morning report.

We would strongly suggest that our readers peruse that report if you didn’t already. The stock is still at a relative bottom as a high sub-penny, compared to the penny-plus marks it has been hitting recently. The potential for near-term gains of at least 100% is definitely present, and we don’t want anyone to miss out. Stay tuned for future reports going into further detail on VISM.


Extended Watchlist:

Blue Horseshoe Stocks Special Report

Visium Technologies, Inc. (OTCMKTS:VISM)
(d.b.a. Visium Analytics)

We are kicking off coverage of another exciting new play with yet another special report this morning. For those who may not recall, earlier this month, we featured reports on an OTC nanotech play which subsequently ran 130% from .05-.116 in a matter of weeks.

Today we are introducing our readers to VISM, a Virginia-based data analytics and cybersecurity firm. Like our recent successful pick, VISM has technical upside potential which we will get into in just a moment- but also has solid substance and a technology partnership with a NASDAQ-traded company that is well known to us. So one thing we want to do is examine VISM‘s connection with Nutanix, Inc. (NASDAQ:NTNX) a little further before delving into what we like about the actual chart.


Nutanix is a leader in the field of hyper converged infrastructures (HCI) and enterprise cloud computing. The company has formed a strategic technology partnership with VISM to provide enhanced cybersecurity visibility and remediation through Visium’s CyGraph technology, which we’ll detail in the next section.

NTNX is well known to us, having appeared in our morning reports on many occasions in the past, as you can see with a quick tag search of our archives. VISM also has other strategic alliances that you can read about in more detail at this page.

This morning’s fresh new release, which you’ll find further down the page hints an even further expansion of the relationship between the two companies.



CyGraph is a cutting-edge data analytics and visualization platform with a cybersecurity focus, that delivers:

  • Asset profile collection, tracking and telemetry, in real-time.
  • Intuitive maps and topologies of the infrastructure (white board approved!).
  • A real-time root causal analysis engine and visualizer.
  • Predictive and visual event warnings – for paths & assets.
  • Cyber health scoring system in compliance with standard CVE & CVSS metrics.
  • Universal data ingestion engine, delivering a single view of the enterprise using data received from disparate cyber and system management tools.>>More CyGraph Info HERE…



It’s not just the company’s technology and vision that interests us. In terms of technical attractiveness, VISM boasts the same type of high subpenny-low penny volatility that can make a trader’s day, week, or month!

The stock had been flirting with the subpenny to penny barrier for the past several weeks, and only just this week has it begun to make a more convincing push into Pennyland- just yesterday, it reached a high of .016. Volume has been on the rise as well.

From VISM‘s closing price of .007, a return to yesterday’s highs could come close to or exceed triple-digit percentage gains. Were the stock to find its way back to the highs it saw in August, we would be talking about a far more considerable upswing!  We are certainly coming across this play at a potentially opportune moment, and highly suggest our readers follow our continuing coverage of VISM.



FAIRFAX, VA, Oct. 30, 2019 (GLOBE NEWSWIRE) — Visium Technologies, Inc. (OTC: VISM), a provider of big data analytics visualization for cybersecurity, and a Nutanix technology partner, announced today that it successfully unveiled its flagship product, CyGraph, at the .NEXT conference in Copenhagen, Denmark. Visium was the sole big data analytics/cybersecurity sponsor at the conference, which was hosted by Nutanix and featured more than 4,000 attendees from around the world. The event generated numerous customer leads and technology partnership opportunities for Visium. Additionally, Visium further engaged with Nutanix in development efforts to incorporate CyGraph into the Nutanix suite of security tools. (>>VIEW FULL PR)


For more info on VISM, reply directly to this email, and/or visit

Why is $24B Orphan Drug leader bidding on Assets for this $7M Company?

Dear Reader,

Since the Orphan Drug Act was passed in 1983, the global market for development of drugs used to treat rare diseases has skyrocketed.  At that time, drug therapies for such diseases were rarely developed.  That has changed in today's multi-billion dollar market. 

Orphan diseases are often overlooked by the pharmaceutical industry, since there is very little financial incentive to treat illnesses which affect fewer than 200,000 people nationwide.  This includes ailments such as Cystic Fibrosis, Lou Gehrig’s disease, Huntington’s disease, and Tourette’s Syndrome.

Alexion Pharmaceuticals, a $24 Billion dollar Biopharma, has become the Orphan Drug leader with over $1.1 Billion in sales last year.  When the company finds a drug with leading-edge science behind it, they go after it

Savvy investors know just where to look to find the next big drug.  Court filings have revealed that Alexion has just received the winning bid on assets from this $7M microcap company, and Wall Street hasn’t caught on yet….until now